Cancer stem cell targeting using the alpha-particle emitter, 213Bi: Mathematical modeling and feasibility analysis

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 1, 2008, Pages 74-81

  Sgouros, George ^a   Song, Hong ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

213Bi; Alpha particle; Modeling; Radioimmunotherapy; Treatment planning

Indexed keywords

BISMUTH 213; MEMBRANE ANTIGEN; RADIOISOTOPE;

ALPHA RADIATION; ARTICLE; CANCER STEM CELL; CELL RENEWAL; CONTROLLED STUDY; DNA DAMAGE; DRUG HALF LIFE; FEASIBILITY STUDY; HUMAN; HUMAN CELL; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; PHENOTYPE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TREATMENT FAILURE; TREATMENT PLANNING;

ALPHA PARTICLES; ANTIBODIES, MONOCLONAL; BISMUTH; BREAST NEOPLASMS; FEASIBILITY STUDIES; HUMANS; MATHEMATICS; MODELS, THEORETICAL; NEOPLASTIC STEM CELLS; RADIOIMMUNOTHERAPY; RADIOISOTOPES;

EID: 39749083272     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.0408     Document Type: Article

References (34)

1. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645.
2. Al Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983.
3. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004;432:396.
4. Balic M, Lin H, Young L, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006;12:5615.
5. Wicha MS. Cancer stem cells and metastasis: Lethal seeds - commentary. Clin Cancer Res 2006;12:5606.
6. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105.
7. Al Hajj M, Becker MW, Wichal M, et al. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 2004;14:43.
8. Costello RT, Mallet F, Gaugler B, et al. Human acute myeloid leukemia CD34(+)/CD38(-) progenitor cells have decreased sensitivity to chemotherapy and fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 2000;60:4403.
9. Bloomer WD, McLaughlin WH, Neirinckx RD, et al. Astatine-211 - tellurium radiocolloid cures experimental malignant ascites. Science 1981;212:340.
10. Macklis RM, Kinsey BM, Kassis AI, et al. Radioimmunotherapy with alpha-particle emitting immunoconjugates. Science 1988;240:1024.
11. Zalutsky MR, Garg PK, Friedman HS, et al. Labeling monoclonal antibodies and F(ab′)2 fragments with the alpha-particle-emitting nuclide astatine-211: Preservation of immunoreactivity and in vivo localizing capacity. Proc Natl Acad Sci USA 1989;86:7149.
12. McDevitt MR, Ma D, Lai LT, et al. Tumor therapy with targeted atomic nanogenerators. Science 2001;294:1537.
13. Sgouros G. Radioimmunotherapy of micrometastases. In: Riva P, ed. Cancer Radioimmunotherapy - Present and Future. Newark, NJ: Harwood Academic, 1998: 191.
14. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998;25:1341.
15. Barendsen GW, Walter HMD. Effects of different ionizing radiations on human cells in tissue culture. 4. Modification of radiation damage. Radiat Res 1964;21:314.
16. 213Bi]anti-CD45 antibodies in leukemia cells. Cancer Res 2007;67:1950.
17. Song H, Shahverdi K, Fox J, et al. Targeting HER2/neu expressing micrometastases in HER2/neu transgenic mice using alpha-particle-emitting monoclonal antibody [(BI)-B-213-7.16.4]. Cancer Biother Radiopharm 2006;21:396.
18. Goddu SM, Howell RL, Bouchet LG, et al. MIRD cellular S values. Reston, VA: Society of Nuclear Medicine, 1997.
19. Hamacher KA, Den RB, Den EI, et al. Cellular dose conversion factors for alpha-particle-emitting radionuclides of interest in radionuclide therapy. J Nucl Med 2001;42:1216.
20. Kvinnsland Y, Stokke T, Aurlien E. Radioimmunotherapy with alpha-particle emitters: Microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei. Radiat Res 2001;155:288.
21. Press WH, Teukolsky SA, Vetterling WT, et al. Numerical Recipe in Fortran 77: The Art of Scientific Computing. Cambridge University Press, 2001.
22. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations. J Nucl Med 1993;34:689.
23. Junghans RP, Sgouros G, Scheinberg DA. Antibody-based immunotherapies of cancer. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy. Philadelphia, PA: Lippincott-Raven, 1996:655.
24. Sgouros G, Graham MC, Divgi CR, et al. Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia. J Nucl Med 1993;34:422.
25. Shepard HM, Lewis GD, Sarup JC, et al. Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic. J Clin Immunol 1991;11:117.
26. Ballangrud AM, Yang WH, Palm S, et al. Alpha-particle emitting atomic generator (actinium-225)-labeled trastuzumab (Herceptin) targeting of breast cancer spheroids: Efficacy versus HER2/neu expression. Clin Cancer Res 2004;10:4489.
27. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002;100:1233.
28. 213Bi-labeled antibody constructs for clinical use. J Nucl Med 1999;40:1722.
29. Snyder WS, Cook MJ, Nasset ES, et al. Report of the task group on reference man, ICRP publication 23. Elmsford, NY. International Commission on Radiological Protection, 1975.
30. Aladhadh AN, Cavill I. Assessment of cellularity in bone-marrow fragments. J Clin Pathol 1983;36:176.
31. Watchman CJ, Jokisch DW, Patton PW, et al. Absorbed fractions for alpha-particles in tissues of trabecular bone: Considerations of marrow cellularity within the ICRP reference male. J Nucl Med 2005;46:1171.
32. Sgouros G, Bolch WE, Shah A, et al. Relative biological effectiveness for efficacy and toxicity in leukemia patients of the alpha-particle emitter, bismuth-213. Cancer Biother Radiopharm 2006;21:397.
33. Schulenburg A, Ulrich-Pur H, Thurnher D, et al. Neoplastic stem cells: A novel therapeutic target in clinical oncology. Cancer 2006;107:2512.
34. 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med 1999;40:1935.